BiotechTube
CorFlow Therapeutics

CorFlow Therapeutics

Baar, Switzerland· Est.
corflow.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

CorFlow Therapeutics is developing the CoFI System, a novel interventional device aimed at addressing the critical unmet need of microvascular obstruction (MVO) following a heart attack. The system is designed to seamlessly integrate into the existing PCI workflow to both diagnose MVO in real-time and potentially deliver targeted therapeutics. With clinical data pending from its MOCA trials, CorFlow is positioning itself to potentially improve long-term cardiac outcomes by enabling early detection and intervention for a complication that currently lacks a routine intra-procedural solution.

Cardiovascular

Technology Platform

The Controlled Flow Infusion (CoFI) System, a catheter-based theranostic platform designed to integrate into PCI procedures. It diagnoses microvascular obstruction (MVO) by measuring coronary flow and can deliver targeted therapeutic agents via controlled infusion.

Funding History

1
Total raised:$20M
Series A$20M

Opportunities

The CoFI System addresses a large, unserved patient population (up to 60% of STEMI patients) with a complication linked to poor long-term outcomes.
Its integration into the existing PCI workflow facilitates potential adoption.
The platform's therapeutic delivery capability opens a future path for combination therapies and expansion into other vascular beds.

Risk Factors

The company's viability depends entirely on positive data from its pending pivotal MOCA II clinical trial.
Post-approval, it faces the challenge of driving adoption of a new device in a standardized procedural environment.
Competition from alternative diagnostic methods or therapies for microvascular dysfunction also poses a risk.

Competitive Landscape

Direct competition for real-time MVO detection during PCI is limited, as the current gold standard (CMRI) is a post-procedural imaging technique. However, CorFlow may compete for cath lab mindshare and budget against other adjunctive PCI devices. In the broader space of post-MI heart failure prevention, it faces indirect competition from pharmaceutical and other device-based approaches under development.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →